Searching for Biotech Firms The search is for firms biotech firms that have reached clinical stage with novel products that had some earlier, encouraging test results, whose technologies and lead products must have demonstrated  improvement over current treatments of devastating diseases, including cancers and genetic-derived diseases.   Recently, we became interested in a firm called Acumen’s Pharmaceuticals (

Acumen Pharmaceuticals Product ACU193 On October 23, 2022, Acumen Pharmaceuticals (ABOS) announced that the first clinical-stage monoclonal antibody ACU193 - an anti-amyloid beta oligomer antibody, which selectively targets toxic soluble amyloid beta oligomers (AβOs), has been granted  FDA Fast Track designation for the treatment of early Alzheimer . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Gilead Sciences and MacroGenics Collaboration Announcement Gilead Sciences (GILD) and MacroGenics (MGNX) announced an exclusive option and collaboration agreement to develop MGD024 using MacroGenics DART . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Reata Pharmaceuticals Announcement Regarding the NDA for Omaveloxolone for Friedreich’s Ataxia Reata Pharmaceuticals (RETA) announced that the U.S. Food and Drug Administration (FDA) does not plan to hold an advisory committee meeting in connection with its review of the Company’s New Drug Application (NDA) for omaveloxolone for the treatment of patients with Friedreich’s ataxia. From Reata Pharmaceuticals CEO Warren Huff, Reata’s Chief Executive Officer, said, …

IgA Nephropathy  Searching for companies focused on treating severe diseases that have yet to find approved drugs is one of Prohost Biotech's tasks.  Recently we wrote about firms that have, in their pipelines, products that aim at treating NASH and ALS.  Now, we are currently interested in finding firms that have products that can successfully treat IgA nephropathy, among other diseases that have yet to …

Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis  The efforts spent on treating Non Alcoholic Steatohepatitis (NASH) have reached a promising stage where clinical trial data from the clinical-stage and revenue-generating biotech firms have demonstrated capability of treat NASH. The most promising of these firms we believe, are clinical-stage firms, especially those firms that have already demonstrated capability of regressing fibrosis in …